A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Proteinase 3 Antibody
MessageSendout, Mayo test code: PR3
Test Code
LAB5210332
Alias/See Also
Autoantibodies to Proteinase 3
c-ANCA (Antineutrophil Cytoplasmic Antibodies)
cANCA (Antineutrophil Cytoplasmic Antibodies)
Cytoplasmic Neutrophil Antibodies
Neutrophil Cytoplasmic Antibodies
pANCA (Perinuclear Antineutrophil Cytoplasmic Antibodies)
Perin
c-ANCA (Antineutrophil Cytoplasmic Antibodies)
cANCA (Antineutrophil Cytoplasmic Antibodies)
Cytoplasmic Neutrophil Antibodies
Neutrophil Cytoplasmic Antibodies
pANCA (Perinuclear Antineutrophil Cytoplasmic Antibodies)
Perin
CPT Codes
83516
Preferred Specimen
0.5 mL serum from a red tube
Minimum Volume
0.35 mL
Other Acceptable Specimens
Serum gel tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 21 days
Frozen: 21 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: OK
Gross lipemia: Reject
Gross icterus: OK
Methodology
Multiplex Flow Immunoassay
FDA Status
Approved
Setup Schedule
Monday through Saturday
Report Available
1-3 days
Limitations
While the presence of proteinase 3 antineutrophil cytoplasmic antibodies (PR3 ANCA) is highly specific for Wegener granulomatosis (WG), it is recommended that positive test results obtained by immunoassay be confirmed by another testing method.(4) This is best accomplished by testing for cytoplasmic ANCA (cANCA) and perinuclear ANCA (pANCA) by indirect immunofluorescence microscopy (ANCA / Cytoplasmic Neutrophil Antibodies, Serum). Alternately, VASC / Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum includes tests for PR3 ANCA, myeloperoxidase antibodies, and, if indicated, cANCA and pANCA. This panel is recommended for the initial diagnostic evaluation of patients clinically suspected of having systemic vasculitis. The simultaneous presence of PR3 ANCA and cANCA has a specificity greater than 99% for WG.(3)
Reference Range
Included with report
Clinical Significance
Evaluating patients suspected of having Wegener granulomatosis (WG)
Distinguishing between WG and other forms of vasculitis, in conjunction with:
-MPO / Myeloperoxidase Antibodies, IgG, Serum
-ANCA / Cytoplasmic Neutrophil Antibodies, Serum (may be obtained as VASC / Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum)
May be useful to follow treatment response or to monitor disease activity in patients with myeloperoxidase antibodies
Distinguishing between WG and other forms of vasculitis, in conjunction with:
-MPO / Myeloperoxidase Antibodies, IgG, Serum
-ANCA / Cytoplasmic Neutrophil Antibodies, Serum (may be obtained as VASC / Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum)
May be useful to follow treatment response or to monitor disease activity in patients with myeloperoxidase antibodies
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Proteinase 3 Antibodies, IgG, Serum